<DOC>
	<DOC>NCT02249871</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate the influence of omeprazole on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in healthy subjects.</brief_summary>
	<brief_title>Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Male or female age 1875 years (both inclusive) at time of signing informed consent Body mass index of 18.529.9 kg/m^2 (both inclusive) A good general health based on medical history, physical examination, and results of vital signs, electrocardiogram and laboratory safety tests performed during the screening visit, as judged by the investigator Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods. Female of child bearing potential must use effective methods of birth control for the duration of the trial and for 5 weeks following last dose. Only highly effective methods of birth control are accepted (i.e., one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives, and some intrauterine devices) History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease Hypertension (defined as sitting systolic blood pressure above or equal to 140 mmHg and/or diastolic blood pressure above or equal to 90 mmHg). If whitecoat hypertension is suspected at the screening visit a repeated measurement is allowed Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>